应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
09606 映恩生物-B
开市前 08-14 09:27:43
192.000
+0.000
0.00%
最高
192.000
最低
192.000
成交量
300.00
今开
192.000
昨收
192.000
日振幅
0.00%
总市值
174.38亿
流通市值
174.38亿
总股本
9,082万
成交额
5.76万
换手率
0.00%
流通股本
9,082万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
【券商聚焦】招商证券首予映恩生物（09606）强烈推荐评级 指ADC管线差异化优势显著
金吾财讯 · 08-12 14:39
【券商聚焦】招商证券首予映恩生物（09606）强烈推荐评级 指ADC管线差异化优势显著
异动解读｜映恩生物-B盘中上涨5.28%，生物科技板块集体走强延续估值修复
行情直击 · 08-11 11:52
异动解读｜映恩生物-B盘中上涨5.28%，生物科技板块集体走强延续估值修复
异动解读｜映恩生物-B盘中上涨5.09%，生物科技板块整体走强带动反弹延续
行情直击 · 08-07
异动解读｜映恩生物-B盘中上涨5.09%，生物科技板块整体走强带动反弹延续
映恩生物-B更新2026年7月股份变动月报表，总股本增至91,224,314股
公告速递 · 08-05
映恩生物-B更新2026年7月股份变动月报表，总股本增至91,224,314股
异动解读｜映恩生物-B盘中上涨5.15%，创新药板块情绪回暖叠加突破性疗法认定提振
行情直击 · 08-04
异动解读｜映恩生物-B盘中上涨5.15%，创新药板块情绪回暖叠加突破性疗法认定提振
异动解读｜映恩生物-B盘中下跌5.23%，GSK竞争压力与减持忧虑延续
行情直击 · 08-03
异动解读｜映恩生物-B盘中下跌5.23%，GSK竞争压力与减持忧虑延续
一周港股牛熊榜 | 海致科技周涨40%问鼎牛榜榜首；清盘人重启股权出售计划，恒大物业周涨23%；伟禄科技暴跌33%，遭大股东减持12%
老虎资讯综合 · 07-31
一周港股牛熊榜 | 海致科技周涨40%问鼎牛榜榜首；清盘人重启股权出售计划，恒大物业周涨23%；伟禄科技暴跌33%，遭大股东减持12%
【券商聚焦】中国银河证券首予映恩生物(09606)推荐评级 指其ADC管线梯队完善
金吾财讯 · 07-21
【券商聚焦】中国银河证券首予映恩生物(09606)推荐评级 指其ADC管线梯队完善
异动解读｜映恩生物-B盘中下跌5.15%，报228.4港元
行情直击 · 07-21
异动解读｜映恩生物-B盘中下跌5.15%，报228.4港元
港股异动 | 映恩生物-B(09606.HK)午后涨近15% B7-H3 ADC拟纳入突破性疗法
智通财经 · 07-20
港股异动 | 映恩生物-B(09606.HK)午后涨近15% B7-H3 ADC拟纳入突破性疗法
异动解读｜映恩生物-B盘中上涨7.07%，DB-1310临床数据披露叠加合作方Avenzo完成纳斯达克上市
行情直击 · 07-20
异动解读｜映恩生物-B盘中上涨7.07%，DB-1310临床数据披露叠加合作方Avenzo完成纳斯达克上市
异动解读｜映恩生物-B盘中下跌5.99%，报220.8港元
行情直击 · 07-17
异动解读｜映恩生物-B盘中下跌5.99%，报220.8港元
创新药连续大涨，这次真的不一样了吗？
华尔街见闻 · 07-16
创新药连续大涨，这次真的不一样了吗？
异动解读｜映恩生物-B盘中上涨6.27%，东吴证券首予买入评级目标价418.61港元
行情直击 · 07-10
异动解读｜映恩生物-B盘中上涨6.27%，东吴证券首予买入评级目标价418.61港元
【券商聚焦】东吴证券首予映恩生物(09606)买入评级 指核心管线疗效显著
金吾财讯 · 07-08
【券商聚焦】东吴证券首予映恩生物(09606)买入评级 指核心管线疗效显著
异动解读｜映恩生物-B盘中上涨5.33%，东吴证券首予买入评级目标价418.61港元
行情直击 · 07-08
异动解读｜映恩生物-B盘中上涨5.33%，东吴证券首予买入评级目标价418.61港元
东吴证券：首予映恩生物(09606.HK)“买入”评级 目标价418.61港元
智通财经 · 07-08
东吴证券：首予映恩生物(09606.HK)“买入”评级 目标价418.61港元
映恩生物-B发布6月股份变动月报，已发行股份增加68,600股
公告速递 · 07-07
映恩生物-B发布6月股份变动月报，已发行股份增加68,600股
异动解读｜映恩生物-B盘中下跌5.07%，报213.4港元
行情直击 · 07-07
异动解读｜映恩生物-B盘中下跌5.07%，报213.4港元
异动解读｜映恩生物-B盘中上涨9.01%，科创板IPO审核状态变更为已问询叠加ADC赛道持续催化
行情直击 · 07-06
异动解读｜映恩生物-B盘中上涨9.01%，科创板IPO审核状态变更为已问询叠加ADC赛道持续催化
加载更多
公司概况
公司名称：
映恩生物-B
所属市场：
SEHK
上市日期：
--
主营业务：
映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物。该公司的主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310、DB-1305/BNT325、DB-1419和DB-2304。该公司的产品主要用于靶向治疗子宫内膜癌（EC）、乳腺癌（BC）、小细胞肺癌（SCLC）、去势抵抗性前列腺癌（CRPC）、食管鳞状细胞癌（ESCC）及头颈部鳞状细胞癌（HNSCC）。该公司主要在国内和国外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":192,"timestamp":1786670402574,"preClose":192,"halted":0,"volume":300,"delay":0,"changeRate":0,"floatShares":90824200,"shares":90824200,"eps":-39.8,"marketStatus":"开市前","change":0,"latestTime":"08-14 09:27:43","open":192,"high":192,"low":192,"amount":57600,"amplitude":0,"askPrice":195.1,"askSize":500,"bidPrice":192,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-31.631,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786671000000},"marketStatusCode":1,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":192,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":0,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09606","defaultTab":"news","newsList":[{"id":"2658921431","title":"【券商聚焦】招商证券首予映恩生物（09606）强烈推荐评级 指ADC管线差异化优势显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2658921431","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658921431?lang=zh_cn&edition=full","pubTime":"2026-08-12 14:39","pubTimestamp":1786516786,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招商证券发布研报指，映恩生物 凭借四大自主知识产权ADC技术平台，构建了覆盖肿瘤与自免疾病、从1.0到3.0全梯度的差异化管线。DB-1303针对二线及以上HER2阳性乳腺癌的III期研究已达PFS主要终点，中国BLA于2026年4月获NMPA受理；其子宫内膜癌适应症获中美突破性疗法认定，为全球少数覆盖全HER2表达水平的HER2 ADC。首次覆盖，给予“强烈推荐”投资评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988027","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","ADC","06099","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106331638","title":"异动解读｜映恩生物-B盘中上涨5.28%，生物科技板块集体走强延续估值修复","url":"https://stock-news.laohu8.com/highlight/detail?id=1106331638","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106331638?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:52","pubTimestamp":1786420323,"startTime":"0","endTime":"0","summary":"8月11日，映恩生物-B盘中上涨5.28%，报205.4港元，成交额1.03亿港元。该股此前因GSK竞争压力于7月30日大跌后持续修复，本次上涨主要受生物科技板块集体走强带动。消息面上，同行业个股今日普涨，百济神州涨4.41%、再鼎医药涨4.6%、康方生物涨2.76%，板块情绪延续回暖。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172376984","title":"异动解读｜映恩生物-B盘中上涨5.09%，生物科技板块整体走强带动反弹延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1172376984","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172376984?lang=zh_cn&edition=full","pubTime":"2026-08-07 14:17","pubTimestamp":1786083478,"startTime":"0","endTime":"0","summary":"8月7日，映恩生物-B盘中上涨5.09%，报191.9港元，成交额1.48亿港元。该股此前因GSK竞争压力于7月30日大跌13.7%，近期逐步企稳修复。消息面上，港股生物科技板块今日整体走强，荣昌生物涨9.12%、药捷安康-B涨6.94%、百济神州涨5.16%、康方生物涨4.06%，板块情绪显著回暖带动映恩生物跟涨。此外，公司核心管线B7-H3 ADC此前获NMPA突破性疗法认定，科创板IPO申请已获上交所受理并进入已问询阶段，多家券商给予\"买入\"评级，基本面利好持续积累支撑估值修复。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B盘中上涨5.09%，生物科技板块整体走强带动反弹延续","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160159290","title":"映恩生物-B更新2026年7月股份变动月报表，总股本增至91,224,314股","url":"https://stock-news.laohu8.com/highlight/detail?id=1160159290","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160159290?lang=zh_cn&edition=full","pubTime":"2026-08-05 16:49","pubTimestamp":1785919773,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年8月5日披露2026年7月股份变动月报表。报告显示，截至本月末，公司法定注册股本维持在200,000,000股普通股不变，每股面值0.0001美元，法定注册股本总额保持在20,000美元。公司表示，其已符合香港联交所主板上市规则相关的公众持股量最低要求。公司亦确认，其在本月的所有股份发行或库存股出售与转让事宜均严格遵照香港联交所《上市规则》和相关法律法规的规定执行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123746970","title":"异动解读｜映恩生物-B盘中上涨5.15%，创新药板块情绪回暖叠加突破性疗法认定提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1123746970","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123746970?lang=zh_cn&edition=full","pubTime":"2026-08-04 13:23","pubTimestamp":1785820995,"startTime":"0","endTime":"0","summary":"8月4日，映恩生物-B盘中上涨5.15%，报189.8港元，成交额1.3亿港元。此前该股因GSK竞争压力连续调整，7月30日大跌13.7%，8月3日再跌5.23%，当前出现明显反弹。消息面上，药明康德半年报业绩超预期并全面上调全年指引，显著提振创新药产业链信心，港股通创新药ETF整体走强，映恩生物-B受板块情绪带动。此外，公司核心管线B7-H3 ADC Elfe-D近期获NMPA突破性疗法认定，海内外均获监管认可，多家券商给予\"买入\"评级，基本面支撑逐步修复市场信心。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B盘中上涨5.15%，创新药板块情绪回暖叠加突破性疗法认定提振","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174620861","title":"异动解读｜映恩生物-B盘中下跌5.23%，GSK竞争压力与减持忧虑延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1174620861","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174620861?lang=zh_cn&edition=full","pubTime":"2026-08-03 09:45","pubTimestamp":1785721512,"startTime":"0","endTime":"0","summary":"8月3日，映恩生物-B盘中下跌5.23%，报172.6港元，成交额2716.64万港元。消息面上，此前葛兰素史克（GSK）在半年报中大幅提升其B7-H3 ADC管线Ris-Rez的战略优先级，将其定义为2031年后肿瘤业务增长核心，直接冲击映恩生物核心管线DB-1311的竞争格局。该股7月30日已大跌13.7%，当前延续调整态势。此外，市场对基石投资者解禁后的减持压力亦存担忧，叠加公司行权Co-Co模式后需持续投入大量研发资金，资金链压力受到关注。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181533841","title":"一周港股牛熊榜 | 海致科技周涨40%问鼎牛榜榜首；清盘人重启股权出售计划，恒大物业周涨23%；伟禄科技暴跌33%，遭大股东减持12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181533841","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181533841?lang=zh_cn&edition=full","pubTime":"2026-07-31 19:35","pubTimestamp":1785497713,"startTime":"0","endTime":"0","summary":"7月全月恒指累升3,003点或13.1%。该股7月21日盘中一度跌33%至111港元，此前7月17日尚报203.60港元。张先生通过其或透过其控制的实体计划于未来6个月增持价值介乎3.0亿港元至6.0亿港元的股份。下一步，计划邀请潜在买方对集团进行尽职调查。出售事项后，美林控股持有7.33亿股股份，占本公司已发行股本总额约50.83%。美林控股进一步告知董事会，据其深知、尽悉及确信，于出售事项前，买方为本公司及其关连人士的独立第三方","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01196","09903","09606","02706","02687","06166","06887","01888","01783","06666"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653221532","title":"【券商聚焦】中国银河证券首予映恩生物(09606)推荐评级 指其ADC管线梯队完善","url":"https://stock-news.laohu8.com/highlight/detail?id=2653221532","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653221532?lang=zh_cn&edition=full","pubTime":"2026-07-21 15:31","pubTimestamp":1784619085,"startTime":"0","endTime":"0","summary":"DB-1303安全性可控，HER2阳性乳腺癌已递交上市申请，填补HER2低表达患者治疗空白。DB-1310针对EGFR靶向耐药肺癌，多线人群ORR达43.5%。DB-1305联合双抗一线三阴性乳腺癌确认超高缓解率。创新管线中，全球首创自免ADC DB-2304靶向BDCA2，直击红斑狼疮未满足临床需求，已推进至IIa期。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986406","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","ADC","161027","601881","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111245137","title":"异动解读｜映恩生物-B盘中下跌5.15%，报228.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111245137","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111245137?lang=zh_cn&edition=full","pubTime":"2026-07-21 10:15","pubTimestamp":1784600144,"startTime":"0","endTime":"0","summary":"7月21日，映恩生物-B盘中下跌5.15%，报228.4港元/股，成交额5300.47万港元。映恩生物-B所在的生物科技行业整体走弱，个股中，百济神州跌2.19%，康方生物跌3.05%，信达生物跌2.49%，科伦博泰生物跌0.99%，三生制药跌2.24%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物创新药物，主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310等，公司主要在国内和国外市场开展业务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652262259","title":"港股异动 | 映恩生物-B(09606.HK)午后涨近15% B7-H3 ADC拟纳入突破性疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2652262259","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652262259?lang=zh_cn&edition=full","pubTime":"2026-07-20 13:38","pubTimestamp":1784525921,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2543165471.USD","HK0000252152.HKD","09606","HK0000500386.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196132904","title":"异动解读｜映恩生物-B盘中上涨7.07%，DB-1310临床数据披露叠加合作方Avenzo完成纳斯达克上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1196132904","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196132904?lang=zh_cn&edition=full","pubTime":"2026-07-20 10:32","pubTimestamp":1784514722,"startTime":"0","endTime":"0","summary":"7月20日，映恩生物-B盘中上涨7.07%，报230.2港元/股，成交额1.19亿港元。消息面上，公司近日在ASCO大会上以口头报告形式首次公布DB-1310用于治疗晚期实体瘤患者的I/IIa期试验初步结果，该品种此前已与阿斯利康就联合奥希替尼的临床探索达成合作。同时，合作方Avenzo于7月16日宣布通过反向合并实现纳斯达克上市，并完成2.15亿美元超额认购PIPE融资，其核心资产之一即为从映恩生物引进的EGFR/HER3双抗ADC DB-1418，进一步验证公司管线商业价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119752477","title":"异动解读｜映恩生物-B盘中下跌5.99%，报220.8港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119752477","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119752477?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:01","pubTimestamp":1784253660,"startTime":"0","endTime":"0","summary":"7月17日，映恩生物-B盘中下跌5.99%，报220.8港元/股，成交额5256.0万港元。映恩生物-B所在的生物科技行业整体走弱，个股中，康方生物跌7.71%，三生制药跌6.98%，科伦博泰生物跌4.65%，信达生物跌2.49%，百济神州跌2.15%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物，主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324等，公司主要在国内和国外市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651341039","title":"创新药连续大涨，这次真的不一样了吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2651341039","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651341039?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:05","pubTimestamp":1784192720,"startTime":"0","endTime":"0","summary":"政策上，医保初审通过率创新高，定价机制优化，并建立“医保+商保”双层支付体系；产业上，上半年BD交易总额达1100亿美元，国际竞争力显著提升；资金面上，内外资持续回流。行业正从“讲故事”转向盈利兑现，国金证券认为，2027年有望成为中国创新药海外商业化集中兑现的重要节点。","market":"hk","thumbnail":"https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3777107","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06618","02269","02359","IBBQ","06996","03347","09966","09995","09688","BK1574","159992","02137","01672","06978","06606","02268","BK1161","03759","MEDX","00241","06622","01801","09606"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1121533022","title":"异动解读｜映恩生物-B盘中上涨6.27%，东吴证券首予买入评级目标价418.61港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1121533022","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121533022?lang=zh_cn&edition=full","pubTime":"2026-07-10 09:47","pubTimestamp":1783648050,"startTime":"0","endTime":"0","summary":"7月10日，映恩生物-B盘中上涨6.27%，报217.0港元/股，成交额3336.27万港元。消息面上，东吴证券近日首次覆盖映恩生物-B，给予\"买入\"评级，目标价418.61港元，较当前股价存在近90%的上行空间。映恩生物是一家全球性临床阶段生物制药公司，致力于研发抗体偶联药物创新疗法，核心候选药物包括DB-1303/BNT323、DB-1311/BNT324等，主要用于靶向治疗多种实体瘤。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649965515","title":"【券商聚焦】东吴证券首予映恩生物(09606)买入评级 指核心管线疗效显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2649965515","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649965515?lang=zh_cn&edition=full","pubTime":"2026-07-08 15:14","pubTimestamp":1783494860,"startTime":"0","endTime":"0","summary":"金吾财讯 | 东吴证券发布研报指，映恩生物-B 是一家专注于研发新一代ADC药物的全球领跑者，依托其自主研发的四大ADC技术平台，构建了覆盖HER2、B7-H3、HER3、TROP2等靶点的13条管线矩阵。研报观点聚焦于两款后期管线。公司已于2026年5月行使该产品美国市场共同开发与共同销售的选择权，有望深度参与并分享其海外商业化价值。东吴证券预计公司2026-2028年营业收入分别为20.52/23.95/25.99亿元，同比增速为10.8%/16.7%/8.5%。首次覆盖，给予“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985367","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["601555","KCE","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117672089","title":"异动解读｜映恩生物-B盘中上涨5.33%，东吴证券首予买入评级目标价418.61港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117672089","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117672089?lang=zh_cn&edition=full","pubTime":"2026-07-08 10:00","pubTimestamp":1783476026,"startTime":"0","endTime":"0","summary":"7月8日，映恩生物-B盘中上涨5.33%，报222.0港元/股，成交额7281.16万港元。消息面上，东吴证券当日首次覆盖映恩生物-B，给予\"买入\"评级，目标价418.61港元，较当前股价存在近90%的上行空间。此外，公司科创板IPO审核状态已于近日变更为\"已问询\"，上市审核流程持续推进，叠加此前公司宣布最多4000万美元回购计划及DB-1311/BNT324全球Ⅲ期临床完成首例患者给药等利好，市场情绪偏暖。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649590309","title":"东吴证券：首予映恩生物(09606.HK)“买入”评级 目标价418.61港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649590309","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649590309?lang=zh_cn&edition=full","pubTime":"2026-07-08 09:16","pubTimestamp":1783473398,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09606","BK1161","HK0000252152.HKD","HK0000252160.HKD","LU2543165471.USD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195851382","title":"映恩生物-B发布6月股份变动月报，已发行股份增加68,600股","url":"https://stock-news.laohu8.com/highlight/detail?id=1195851382","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195851382?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:45","pubTimestamp":1783413932,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年7月7日公布截至2026年6月30日的股份变动月报，披露了公司在报告期内的股本结构及相关变动情况。本月公司法定股本未发生变化，维持在2亿股普通股，面值每股0.0001美元，对应注册股本2万美元。根据公告，映恩生物-B在6月内通过首次公开发售前股权激励计划有348,900股股份行权发行，获得行权资金2,361,829.50港元；当月还注销了12,081份股权激励期权，截至6月底该计划剩余18,089,549份期权。截至报告期末，映恩生物-B整体股本有所增加。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153580278","title":"异动解读｜映恩生物-B盘中下跌5.07%，报213.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153580278","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153580278?lang=zh_cn&edition=full","pubTime":"2026-07-07 15:18","pubTimestamp":1783408686,"startTime":"0","endTime":"0","summary":"7月7日，映恩生物-B盘中下跌5.07%，报213.4港元/股，成交额3.8亿港元。映恩生物-B所在的生物科技行业中，板块整体承压回调，个股中，三生制药跌7.2%，康方生物跌4.61%，信达生物跌4.14%，百济神州跌3.67%，科伦博泰生物跌2.87%。映恩生物是一家全球性临床阶段生物制药公司，致力于研发抗体偶联药物（ADC）创新疗法，核心候选药物包括DB-1303/BNT323、DB-1311/BNT324等，主要用于靶向治疗多种实体瘤。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112923173","title":"异动解读｜映恩生物-B盘中上涨9.01%，科创板IPO审核状态变更为已问询叠加ADC赛道持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1112923173","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112923173?lang=zh_cn&edition=full","pubTime":"2026-07-06 09:50","pubTimestamp":1783302612,"startTime":"0","endTime":"0","summary":"7月6日，映恩生物-B盘中上涨9.01%，报232.8港元/股，成交额9939.42万港元。消息面上，公司科创板IPO审核状态已于近日变更为\"已问询\"，标志着上市审核流程进一步推进，此前公司拟募资41亿元用于新药研发。此外，近期行业研报指出全球ADC市场预计于2032年突破千亿美元，中国企业竞争优势愈发显著，映恩生物作为ADC核心标的持续受到关注。行业层面，生物科技板块延续强势，荣昌生物涨4.67%，信达生物涨3.47%，三生制药涨2.4%，科伦博泰生物涨1.7%，康方生物涨1.07%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dualitybiologics.com","stockEarnings":[{"period":"1week","weight":0.0515},{"period":"1month","weight":-0.1382},{"period":"3month","weight":-0.1623},{"period":"6month","weight":-0.4286},{"period":"1year","weight":-0.4646},{"period":"ytd","weight":-0.3561}],"compareEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":0.0434},{"period":"3month","weight":-0.0218},{"period":"6month","weight":-0.0441},{"period":"1year","weight":-0.0085},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"映恩生物是一家主要从事临床阶段生物制药的投资控股公司。该公司致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物（ADC）创新药物。该公司的主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310、DB-1305/BNT325、DB-1419和DB-2304。该公司的产品主要用于靶向治疗子宫内膜癌（EC）、乳腺癌（BC）、小细胞肺癌（SCLC）、去势抵抗性前列腺癌（CRPC）、食管鳞状细胞癌（ESCC）及头颈部鳞状细胞癌（HNSCC）。该公司主要在国内和国外市场开展业务。","exchange":"SEHK","name":"映恩生物-B","nameEN":"DUALITYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"映恩生物-B,09606,映恩生物-B股票,映恩生物-B股票老虎,映恩生物-B股票老虎国际,映恩生物-B行情,映恩生物-B股票行情,映恩生物-B股价,映恩生物-B股市,映恩生物-B股票价格,映恩生物-B股票交易,映恩生物-B股票购买,映恩生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"映恩生物-B(09606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供映恩生物-B(09606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}